Acute generalized exanthematous pustulosis. Study of 22 cases

##plugins.themes.academic_pro.article.sidebar##

Published Nov 29, 2010
Download
pdf
Vol. 88 No. 12 (2010): Issue Dec 2010

##plugins.themes.academic_pro.article.main##

Amel Mebazaa
Rim Kort
Ahmed Zaiem
Dalenda Elleuch
Hela Moula
Rim Cheikhrouhou
Sondes Trojjet
Mourad Mokni
Amel Ben Osman
Riadh Daghfous

Abstract

Background: Acute generalized exanthematous pustulosis (AGEP) is an uncommon but severe dermatosis, characterized by acute occurrence of fever, and erythemato-oedematous rash, covered by sterile nonfollicular pustules. Most cases of AGEP have been described in association with the intake of drugs.
Aim: To determine clinical and prognostic features of AGEP in our patients.
Methods: All cases of AGEP diagnosed between 1992 and 2007 according to EuroSCAR criteria have been collected.
Results: Twenty two patients (16 female, 6 male) with a mean age of 40.9 years (19-81) were included in the study. Clinical features showed in all cases an acute eruption with oedematous erythema, rapidly covered by nonfollicular pustules. The rash was mainly localized on big folds, trunk and/or limbs in 14 cases and generalized in 8 cases. A biological cytolysis was noted in 5 cases and a functional acute renal failure was objected in 2 cases. Etiological work up has found an association with the intake of drugs in 14 cases, a toxic cause (mercury) in 1 case and a B19 parvovirus infection in one case. The mean delay between drug intake and beginning of the eruption was 5 days (24 hours- 15 days). Pharmacovigilance enquiry has concluded to a probable or plausible causality in all our cases.
Clinical features improved with drug or toxic withdrawal with a mean delay of 7 days (4 -12 days). A relapse of AGEP was observed in 2 cases after accidental introduction of the drug.
Conclusion: AGEP is a cutaneous side effect not to ignore, because of its severe prognosis in case of systemic involvement and the possibility of relapses in case of retake of the causal drug.

Keywords:

hepatitis viral C, hemodialysis, kidney transplantation, ,

##plugins.themes.academic_pro.article.details##

References

  1. Beylot C, Bioulac P, Doutre MS. Pustuloses exanthématiques aigues généralisées. A propos de 4 cas. Ann Dermatol Venereol 1980; 107:37-48.
  2. Sidoroff A, Dunant A, Viboud C et al. Risk factors for acute generalized exanthematous pustulosis -results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157: 989- 996.
  3. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis: A clinical reaction pattern. J Cutan Pathol 2001; 28:113-19.
  4. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France. Therapie. 1985;40:111-118
  5. Saissi H, Beau-Salinas F, Jonville-Béra AP, Lorette G, Autret- Leca E; Centres Régionaux de Pharmacovigilance. Drug associated with acute generalized exanthematic pustulosis. Ann Dermatol Venereol. 2003; 130:612-8.
  6. Amouri M, El Euch D, El Ouni B et al. Pustulose exanthématique aiguë généralisée à la terbinafine. Presse Med 2008; 37:547-548.
  7. Bernard PH, Lizieux-Parneix V, Miossec V et al. HLA et prédisposition génétique dans les pustuloses exanthématiques aiguës généralisées et les exanthèmes maculo-papuleux. Ann Dermatol Venereol 1995; 22:S38-9.
  8. Machet L, Martin L, Vaillant L. Pustulose exanthématique aigue généralisée. Ann Dermatol Venereol 2001; 128 :73-9.
  9. Roujeau JC, Bioulac-Sage P, Bourseau C et al. Acute generalized exanthematous pustulosis: 63 cases. Arch Dermatol 1991; 127: 1333-8.
  10. Beylot C, Doutre MS, Beylot-Barry M. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg 1996; 15:244-9.
  11. Thurot C, Reymond JL, Bourrain JL, Pinel N, Beani JC. Pustulose exanthématique aiguë généralisée à la fluindione avec atteinte rénale. Ann Dermatol Venereol 2003; 130: 1146-9.
  12. Crowson AN; Brown TJ; Magro CM. Progress in the Understanding of the Pathology and Pathogenesis of Cutaneous Drug Eruptions: Implications for Management. Am J Clin Dermatology 2003; 4: 407-28.
  13. Buettiker U, Keller M, Pichler WJ, Braathen LR, Yawalkar N. Oral Prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group A confirmed by epicutaneous testing and lymphocyte transformation tests. Dermatology 2006; 213: 40-3.
  14. Mashiah J, Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol 2003; 139:1181-3.
  15. Feio AB, Apetato M, Costa MM, Sa J, Alcantara J. Acute generalized exanthematous pustulosis due to Coxsackie virus. Acta Med Port 1997; 10:487-91.
  16. Kempinaire A, De Reave L, Merckx M, De Coninck A, Bauwens M, Roseeuw D. Terbinafine-induced acute generalized exanthematous pustulosis confirmed by a positive patch-test result. J Am Acad Dermatol 1997; 37:653-5.
  17. Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol 2004; 50:650-1.